Alcon's $200M RxSight partnership aims to recapture IOL market share with adjustable presbyopic lenses. RxSight gets 30% ...
Over the last several years, the RxSight team has been developing proprietary hybrid IOL materials for next-generation light adjustable technology that can support a full suite of adjustable lenses ...
Medical Device Network on MSN
Alcon spends up to $200M to co-develop customisable cataract lenses with RxSight
The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for ...
Alcon (NYSE:ALC) and RxSight (Nasdaq:RXST) announced that they entered into a non-exclusive intraocular lens (IOL) ...
Alcon and RxSight partner to develop light-adjustable presbyopia-correcting IOLs, including $60M upfront and milestone payments.
Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results